• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经喉罩气道给予复苏用表面活性剂的治疗:一项初步试验的经验教训。

Administration of rescue surfactant by laryngeal mask airway: lessons from a pilot trial.

机构信息

Department of Pediatrics, University of Virginia, Charlottesville, VA, USA.

出版信息

Am J Perinatol. 2013 Mar;30(3):201-6. doi: 10.1055/s-0032-1323592. Epub 2012 Aug 14.

DOI:10.1055/s-0032-1323592
PMID:22893557
Abstract

OBJECTIVES

To determine if surfactant can be effectively administered to larger preterm babies by laryngeal mask airway (LMA), reducing the need for supplemental oxygen.

STUDY DESIGN

Enrollment criteria: birth weight > 1200 g, < 72 hours old, treated with nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome, with fraction of inspired oxygen (Fio2) requirement between 0.30 and 0.60. Subjects were randomized either to receive 3 mL/kg calfactant by LMA (experimental) followed by LMA removal back to CPAP, or continued on nCPAP (control). After intervention, both groups remained on nCPAP with Fio2 adjusted to maintain O2 saturations at 88 to 95%.

RESULTS

A total of 26 patients (13 per group) were randomized, and 24 completed the study (11 experimental, 13 control). Groups were similar with respect to gender, mode of delivery, estimated gestational age, birth weight, and oxygen and pressure requirements at enrollment. Infants enrolled in the treatment group had an abrupt and sustained decrease in oxygen requirement after LMA surfactant therapy.

CONCLUSION

This pilot study demonstrates that surfactant can be delivered by LMA, which leads to a significant decrease in supplemental oxygen requirement. Larger controlled trials in low-resource settings may show this technique to be valuable in clinical situations where direct laryngoscopy and intubation are difficult or where resources for mechanical ventilation are limited.

摘要

目的

通过喉罩气道(LMA)向较大的早产儿有效给予表面活性剂,减少对补充氧气的需求。

研究设计

纳入标准:出生体重>1200g,<72 小时,因呼吸窘迫综合征接受鼻持续气道正压通气(nCPAP)治疗,吸入氧分数(Fio2)需求在 0.30 至 0.60 之间。将受试者随机分为通过 LMA 给予 3mL/kg 肺表面活性剂(实验组),然后将 LMA 移除回 CPAP,或继续接受 nCPAP(对照组)。干预后,两组均继续接受 nCPAP,调整 Fio2 以维持氧饱和度在 88%至 95%之间。

结果

共有 26 名患者(每组 13 名)被随机分组,24 名患者完成了研究(实验组 11 名,对照组 13 名)。两组在性别、分娩方式、估计胎龄、出生体重以及入组时的氧气和压力需求方面相似。治疗组的婴儿在接受 LMA 表面活性剂治疗后,氧气需求突然且持续下降。

结论

这项初步研究表明,表面活性剂可以通过 LMA 给予,这可以显著减少补充氧气的需求。在资源有限的情况下,直接喉镜检查和插管困难或机械通气资源有限的临床情况下,更大规模的对照试验可能会证明这种技术具有价值。

相似文献

1
Administration of rescue surfactant by laryngeal mask airway: lessons from a pilot trial.经喉罩气道给予复苏用表面活性剂的治疗:一项初步试验的经验教训。
Am J Perinatol. 2013 Mar;30(3):201-6. doi: 10.1055/s-0032-1323592. Epub 2012 Aug 14.
2
Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery.喉罩气道与气管插管用于表面活性剂给药的随机试验。
J Perinatol. 2016 Mar;36(3):196-201. doi: 10.1038/jp.2015.177. Epub 2015 Dec 3.
3
Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome.喉罩气道用作向患有呼吸窘迫综合征的早产儿给药表面活性剂的输送管道。
Biol Neonate. 2005;87(4):217-20. doi: 10.1159/000083370. Epub 2005 Jan 13.
4
A randomized controlled trial of the laryngeal mask airway for surfactant administration in neonates.一项关于喉罩气道用于新生儿表面活性剂给药的随机对照试验。
J Pediatr (Rio J). 2017 Jul-Aug;93(4):343-350. doi: 10.1016/j.jped.2016.08.007. Epub 2017 Jan 25.
5
Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.喉罩气道给予表面活性剂预防患有或有呼吸窘迫综合征风险的早产儿发病和死亡
Cochrane Database Syst Rev. 2011 Jul 6(7):CD008309. doi: 10.1002/14651858.CD008309.pub2.
6
Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial.经鼻给予肺表面活性物质时使用喉罩气道:一项随机对照试验。
J Pediatr. 2018 Feb;193:40-46.e1. doi: 10.1016/j.jpeds.2017.09.068. Epub 2017 Nov 22.
7
Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial.极早早产儿在接受早期持续气道正压通气治疗时不进行强制通气使用表面活性剂:一项随机对照试验。
Pediatrics. 2009 Jan;123(1):137-42. doi: 10.1542/peds.2007-3501.
8
Use of surfactant for prevention of respiratory distress syndrome in newborn infants in spontaneous breathing. A randomized multicentre clinical pilot-study.表面活性剂用于预防自主呼吸的新生儿呼吸窘迫综合征。一项随机多中心临床试点研究。
Acta Biomed Ateneo Parmense. 1997;68 Suppl 1:39-45.
9
Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial.孕28 - 31周新生儿预防性鼻持续气道正压通气:多中心随机对照临床试验
Arch Dis Child Fetal Neonatal Ed. 2004 Sep;89(5):F394-8. doi: 10.1136/adc.2003.037010.
10
Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial.避免机械通气的表面活性物质治疗自主呼吸早产儿(AMV):一项开放标签、随机、对照试验。
Lancet. 2011 Nov 5;378(9803):1627-34. doi: 10.1016/S0140-6736(11)60986-0. Epub 2011 Sep 29.

引用本文的文献

1
Comparative efficacy and safety of pulmonary surfactant delivery strategies in neonatal RDS: a network meta-analysis.新生儿呼吸窘迫综合征中肺表面活性物质给药策略的比较疗效与安全性:一项网状Meta分析
BMC Pulm Med. 2024 Dec 30;24(1):637. doi: 10.1186/s12890-024-03429-4.
2
Laryngeal Mask for Minimally-invasive Surfactant Administration: A Narrative Review.用于微创表面活性剂给药的喉罩:一篇叙述性综述
Curr Pediatr Rev. 2025;21(2):111-117. doi: 10.2174/0115733963328784240820062714.
3
Feasibility and safety of surfactant administration via laryngeal mask airway as first-line therapy for a select newborn population: results of a standardized clinical protocol.
通过喉罩气道给予表面活性剂作为特定新生儿群体一线治疗的可行性和安全性:一项标准化临床方案的结果
J Perinatol. 2025 Jan;45(1):36-42. doi: 10.1038/s41372-024-02099-8. Epub 2024 Aug 30.
4
Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.喉罩气道表面活性物质给药预防有或有呼吸窘迫综合征风险的早产儿发病率和死亡率。
Cochrane Database Syst Rev. 2024 Jan 25;1(1):CD008309. doi: 10.1002/14651858.CD008309.pub3.
5
Prophylactic Oropharyngeal Surfactant for Preterm Newborns at Birth: A Randomized Clinical Trial.出生时给早产新生儿预防性使用口咽表面活性剂:一项随机临床试验
JAMA Pediatr. 2024 Feb 1;178(2):117-124. doi: 10.1001/jamapediatrics.2023.5082.
6
Comparison of laryngeal mask airway and endotracheal tube placement in neonates.喉罩与气管插管在新生儿中的应用比较。
J Perinatol. 2024 Feb;44(2):239-243. doi: 10.1038/s41372-023-01818-x. Epub 2023 Nov 2.
7
Less invasive surfactant administration methods: Who, what and how.更微创的表面活性物质给药方法:谁、什么和如何。
J Perinatol. 2024 Apr;44(4):472-477. doi: 10.1038/s41372-023-01778-2. Epub 2023 Sep 22.
8
Clinical decision thresholds for surfactant administration in preterm infants: a systematic review and network meta-analysis.早产儿表面活性剂给药的临床决策阈值:一项系统评价和网状荟萃分析。
EClinicalMedicine. 2023 Jul 20;62:102097. doi: 10.1016/j.eclinm.2023.102097. eCollection 2023 Aug.
9
Updates in neonatal resuscitation: routine use of laryngeal masks as an alternative to face masks.新生儿复苏的最新进展:常规使用喉罩作为面罩的替代方法。
Clin Exp Pediatr. 2024 May;67(5):240-246. doi: 10.3345/cep.2023.00619. Epub 2023 Jul 11.
10
Respiratory Management of the Preterm Infant: Supporting Evidence-Based Practice at the Bedside.早产儿的呼吸管理:支持床边循证实践
Children (Basel). 2023 Mar 10;10(3):535. doi: 10.3390/children10030535.